ATE420191T1 - Promotoren zur expression im modifizierten vacciniavirus ankara - Google Patents

Promotoren zur expression im modifizierten vacciniavirus ankara

Info

Publication number
ATE420191T1
ATE420191T1 AT04790902T AT04790902T ATE420191T1 AT E420191 T1 ATE420191 T1 AT E420191T1 AT 04790902 T AT04790902 T AT 04790902T AT 04790902 T AT04790902 T AT 04790902T AT E420191 T1 ATE420191 T1 AT E420191T1
Authority
AT
Austria
Prior art keywords
expression
ankara
promotors
modified
vacciniavirus
Prior art date
Application number
AT04790902T
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE420191T1 publication Critical patent/ATE420191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04790902T 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara ATE420191T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (de) 2003-11-24 2004-01-17 Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Publications (1)

Publication Number Publication Date
ATE420191T1 true ATE420191T1 (de) 2009-01-15

Family

ID=34442836

Family Applications (4)

Application Number Title Priority Date Filing Date
AT07014231T ATE471383T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT07014231T ATE471383T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara

Country Status (18)

Country Link
US (3) US7816508B2 (de)
EP (4) EP1536015B1 (de)
JP (2) JP2007512009A (de)
KR (1) KR20060109873A (de)
CN (1) CN1898390A (de)
AT (4) ATE471383T1 (de)
AU (1) AU2004295382A1 (de)
BR (1) BRPI0416916A (de)
CA (1) CA2546680A1 (de)
DE (4) DE602004027767D1 (de)
DK (3) DK1536015T3 (de)
EA (1) EA012846B1 (de)
IL (4) IL174653A0 (de)
NO (1) NO20062948L (de)
NZ (1) NZ547405A (de)
SG (2) SG169325A1 (de)
UA (1) UA90098C2 (de)
WO (1) WO2005054484A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
ATE471383T1 (de) * 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
EP2042604A1 (de) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
JP2012509678A (ja) * 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
EP3621646A4 (de) * 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Mutanten des vaccinia-virus für die krebsimmuntherapie
CN121443308A (zh) 2023-03-17 2026-01-30 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) 用于治疗乙型肝炎的hbv抗原制剂
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
MXPA02008873A (es) 2000-03-14 2003-02-10 Anton Mayr Cepa alterada del virus de vaccinia ankara modificado (mva).
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
EP2264178A1 (de) * 2002-08-07 2010-12-22 Bavarian Nordic A/S Vaccinia Virus Wirtspektrum Gene zur Erhöhung des Titers von Avipoxviren
ATE471383T1 (de) * 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara

Also Published As

Publication number Publication date
DE602004018975D1 (de) 2009-02-26
IL199127A (en) 2010-12-30
EP1845164B1 (de) 2010-06-16
EA200601043A1 (ru) 2006-10-27
DE602004009743T2 (de) 2008-08-28
EP1956094A1 (de) 2008-08-13
IL199128A (en) 2011-03-31
JP2011067219A (ja) 2011-04-07
CN1898390A (zh) 2007-01-17
US20080112971A1 (en) 2008-05-15
DE602004032187D1 (de) 2011-05-19
EP1536015A1 (de) 2005-06-01
ATE504654T1 (de) 2011-04-15
US20110008792A1 (en) 2011-01-13
NO20062948L (no) 2006-08-23
UA90098C2 (en) 2010-04-12
EP1956094B1 (de) 2011-04-06
DE602004009743D1 (de) 2007-12-13
ATE471383T1 (de) 2010-07-15
JP2007512009A (ja) 2007-05-17
US20110014242A1 (en) 2011-01-20
EP1845164A2 (de) 2007-10-17
CA2546680A1 (en) 2005-06-16
IL174653A0 (en) 2006-08-20
DK1845164T3 (da) 2010-09-20
SG169325A1 (en) 2011-03-30
US7816508B2 (en) 2010-10-19
KR20060109873A (ko) 2006-10-23
EP1689872A1 (de) 2006-08-16
EA012846B1 (ru) 2009-12-30
EP1845164A3 (de) 2008-03-19
WO2005054484A1 (en) 2005-06-16
SG142300A1 (en) 2008-05-28
IL199126A (en) 2010-12-30
ATE377088T1 (de) 2007-11-15
DK1689872T3 (da) 2009-04-27
EP1689872B1 (de) 2009-01-07
AU2004295382A1 (en) 2005-06-16
NZ547405A (en) 2008-06-30
BRPI0416916A (pt) 2007-01-23
DE602004027767D1 (de) 2010-07-29
EP1536015B1 (de) 2007-10-31
DK1536015T3 (da) 2008-02-18

Similar Documents

Publication Publication Date Title
IL199126A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters.
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
NO20045480L (no) Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
IL214460A0 (en) Malaria prime/boost vaccines
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
ATE532861T1 (de) Expressionsvektor
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
BRPI0516576A (pt) vetores quiméricos
WO2002077241A3 (en) Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2003018756A3 (en) Methods for preparing purified prostaglandin e synthase
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
WO2005001096A8 (en) Vaccines against sars
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2003091393A3 (en) Nucleic “acid molecules encoding human proteins, and uses thereof”

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689872

Country of ref document: EP